GSK cuts 24-valent pneumococcal program for adults due to competition

GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Scientists install ‘window’ in the skull to record brain activity using ultrasound

Researchers may have a new way to watch the brain pulse, thanks to an ultrasound probe and a tiny window in the skull. This acoustically

May 29, 2024

Chatbots Not Always Reliable for Cancer Treatment Advice

Chatbots had mixed results when it came to providing direct-to-patient cancer-related advice and treatment strategies for a wide variety of cancers, according to two studies

August 25, 2023

MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability – Biotech Investments

EQS-News: MorphoSys AG / Key word(s): Forecast MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces

January 31, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.